Immunotherapy to fight cancer

Israeli biotech Efranat Ltd. is developing an immunotherapy treatment approach for cancer, based on a glycoprotein named GcMAF (Globulin component Macrophage Activating Factor). Efranat has just raised $4.5 million and is conducting trials at Tel Hashomer’s Sheba Medical Center.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.